|Company Name||Emergent BioSolutions Inc.|
|Class Period||July 6, 2020 to March 31, 2021|
|Motion Deadline||June 18, 2021|
The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Emergent BioSolutions Inc. (NYSE: EBS). The case is currently in the lead plaintiff stage. Investors who purchased EBS stock or other securities between July 6, 2020 and March 31, 2021 may contact the Thornton Law Firm’s investor protection team by submitting their information above. Investors may also email firstname.lastname@example.org or call 617-531-3917.
The case alleges that Emergent and its senior executives made misleading statements to investors and failed to disclose that: (i) Emergent’s Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent’s facility led to a string of U.S. Food and Drug Administration citations; and (iii) Emergent previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards.
Interested Emergent investors have until June 18, 2021 to retain counsel and apply to be a lead plaintiff if they are interested to do so. Investors do not need to be a lead plaintiff in order to be a class member. A lead plaintiff acts on behalf of all other investor class members in managing the class action. If investors choose to take no action, they can remain an absent class member. The class has not yet been certified. Until certification occurs, investors are not represented by an attorney.
Thornton Law Firm’s securities attorneys are highly experienced in representing investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of investors. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
A class action lawsuit has been filed on behalf of investors in Emergent BioSolutions Inc. (EBS) securities.
Please use the form below to provide transaction information.